{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:05:05Z","timestamp":1785243905133,"version":"3.55.0"},"reference-count":197,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>The rapid expansion of biologic therapies for immune-mediated inflammatory diseases has raised significant clinical concerns regarding malignancy risk, particularly for patients with a history of cancer. This narrative review explores the safety of targeted therapies across dermatology, rheumatology, respiratory medicine, and gastroenterology to guide clinicians in these therapeutic dilemmas. We conducted a non-systematic review of the literature, prioritising longitudinal registry and real-world cohort data over clinical trials to better capture malignancy outcomes with long latency periods. Results indicate that tumour necrosis factor (TNF) inhibitors, which have the most extensive evidence base, do not consistently demonstrate an increased risk of overall incident malignancy or recurrence across specialties. Newer agents, including interleukin (IL)-17 and IL-23 inhibitors, show reassuring safety profiles in both trial and registry data. While dupilumab is associated with the potential diagnostic \u2018unmasking\u2019 of pre-existing cutaneous T-cell lymphoma, overall cancer rates remain stable among users. Most clinical guidelines support an individualised, multidisciplinary approach involving oncology consultation. We conclude that biologic agents can be used cautiously in certain patients with a history of malignancy following multidisciplinary discussion; however, in those with active malignancy there are no meaningful data that exist. Most evidence is heterogenous and excludes patients with a history of malignancy. Future management requires validated decision frameworks and mandatory participation in real-world patient co-created registries which leverage developing artificial intelligence tools to refine long-term safety assessments.<\/jats:p>","DOI":"10.3390\/curroncol33080445","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:15:56Z","timestamp":1785140156000},"page":"445","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescribing Biologic Immune-Modifying Therapies for Patients with a History of Cancer: A Cross-Specialty Review"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-820X","authenticated-orcid":false,"given":"Stephanie","family":"Bowe","sequence":"first","affiliation":[{"name":"Dermatology Department, South Infirmary Victoria University Hospital, T12 X23H Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-7336","authenticated-orcid":false,"given":"Seamus","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cork University Hospital, T12 DC4A Cork, Ireland"},{"name":"Cancer Trials Ireland, 123 St. Stephens Green, D02 H903 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-076X","authenticated-orcid":false,"given":"Michelle","family":"Murphy","sequence":"additional","affiliation":[{"name":"Dermatology Department, South Infirmary Victoria University Hospital, T12 X23H Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"O\u2019Mahony","sequence":"additional","affiliation":[{"name":"Respiratory Department, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Harney","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Zulquernain","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bourke","sequence":"additional","affiliation":[{"name":"Dermatology Department, South Infirmary Victoria University Hospital, T12 X23H Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of Psoriasis with the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.0022-202x.2001.01520.x","article-title":"Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden","volume":"117","author":"Boffetta","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: An inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaad.2010.04.046","article-title":"The risk of cancer in patients with psoriasis: A population-based cohort study in Taiwan","volume":"65","author":"Chen","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The Risk of Cancer in Patients with Psoriasis: A Population-Based Cohort Study in the Health Improvement Network","volume":"152","author":"Shin","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","article-title":"Malignant tumours and psoriasis: A follow-up study","volume":"140","author":"Frentz","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","first-page":"1210","article-title":"PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/jdv.20738","article-title":"Risk of adverse events of psoriasis treatment with biologic agents and new small molecules\u2014BIOBADADERM Registry","volume":"39","author":"Carrascosa","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: A collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn\u2019s disease: Results from the TREAT\u2122 Registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","article-title":"Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry","volume":"7","author":"Menter","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16715","article-title":"Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: A meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland","volume":"179","author":"Descalzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti\u2013tumor necrosis factor \u03b1 therapies: Does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ard-2022-222879","article-title":"Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: Final 3-year results from the PsABio real-world study","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant Neoplasms in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden","volume":"177","author":"Frisell","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Andersen","year":"2014","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1007\/s13555-025-01497-w","article-title":"Brodalumab: Seven-Year US Pharmacovigilance Report","volume":"15","author":"Lebwohl","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_26","first-page":"3534","article-title":"Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: Results from the BIOBADASER III registry","volume":"65","author":"Vela","year":"2026","journal-title":"Rheumatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7949","DOI":"10.1038\/s41598-025-90996-z","article-title":"Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-\u03b1 inhibitors: A retrospective nationwide study","volume":"15","author":"Song","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"105900","DOI":"10.1016\/j.jbspin.2025.105900","article-title":"Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE","volume":"92","author":"Morel","year":"2025","journal-title":"Jt. Bone Spine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: A national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2500139","DOI":"10.1183\/13993003.00139-2025","article-title":"Dupilumab and lymphoma risk among patients with asthma: A population-based cohort study","volume":"66","author":"Ma","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/rheumatology\/keae140","article-title":"Cancer risk with tocilizumab\/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: A Danish cohort study","volume":"64","author":"Westermann","year":"2025","journal-title":"Rheumatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Calzari, P., Chiei Gallo, A., Barei, F., Bono, E., Cugno, M., Marzano, A.V., and Ferrucci, S.M. (2024). Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185610"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/ibd\/izab357","article-title":"Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn\u2019s Disease Patients: The SUSTAIN Study","volume":"28","author":"Chaparro","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/bjd\/ljad081","article-title":"Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials","volume":"189","author":"Blauvelt","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term Safety of Secukinumab over Five Years in Patients with Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm.-Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/bjd\/ljaf032","article-title":"Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: Long-term results from the BE RADIANT phase IIIb trial open-label extension period","volume":"193","author":"Warren","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e005026","DOI":"10.1136\/rmdopen-2024-005026","article-title":"Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: Pooled results from integrated phase IIb\/III clinical studies","volume":"11","author":"Mease","year":"2025","journal-title":"RMD Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamadermatol.2025.2056","article-title":"Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data from 25 Randomized Clinical Trials","volume":"161","author":"Merola","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"i167","DOI":"10.1093\/ecco-jcc\/jjad212.0093","article-title":"DOP53 Long-term Efficacy and Safety of Risankizumab in Patients with Moderate to Severe Crohn\u2019s Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension","volume":"18","author":"Ferrante","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn\u2019s Disease and 4 Years in Ulcerative Colitis","volume":"18","author":"Ghosh","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: Pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials*","volume":"187","author":"Simpson","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"LSimpson","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40257-025-00952-w","article-title":"The Safety Data of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults","volume":"26","author":"Langley","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jaip.2024.04.033","article-title":"MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab","volume":"12","author":"Bourdin","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: Results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: Final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: A systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14068","article-title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_57","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clindermatol.2009.03.003","article-title":"Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: Facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clin. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jdv.12162","article-title":"Psoriasis, cardiovascular events, cancer risk and alcohol use: Evidence-based recommendations based on systematic review and expert opinion","volume":"27","author":"Richard","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101472","DOI":"10.1016\/j.berh.2019.101472","article-title":"The relationships between cancer and autoimmune rheumatic diseases","volume":"34","author":"Cappelli","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_62","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Bernal-Bello, D., Frutos-P\u00e9rez, B., Duarte-Mill\u00e1n, M., Toledano-Mac\u00edas, M., Jaenes-Barrios, B., and Morales-Ortega, A. (2025). Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians. J. Clin. Med., 14.","DOI":"10.3390\/jcm14175954"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: An updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J. Autoimmun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: Meta-analysis of population-based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: A metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sjogren\u2019s syndrome and malignancy risk: A systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(19)32545-0","article-title":"Colorectal cancer in ulcerative colitis: A Scandinavian population-based cohort study","volume":"395","author":"Erichsen","year":"2020","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.gastro.2012.04.016","article-title":"Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years","volume":"143","author":"Jess","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1053\/j.gastro.2005.12.037","article-title":"Risk of intestinal cancer in inflammatory bowel disease: A population-based study from olmsted county, Minnesota","volume":"130","author":"Jess","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0140-6736(90)91889-I","article-title":"Increased risk of large-bowel cancer in Crohn\u2019s disease with colonic involvement","volume":"336","author":"Ekbom","year":"1990","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s10350-006-0555-9","article-title":"Crohn\u2019s colitis: The incidence of dysplasia and adenocarcinoma in surgical patients","volume":"49","author":"Maykel","year":"2006","journal-title":"Dis. Colon Rectum"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cgh.2008.03.019","article-title":"Screening and surveillance colonoscopy in chronic Crohn\u2019s colitis: Results of a surveillance program spanning 25 years","volume":"6","author":"Friedman","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/annonc\/mdn595","article-title":"Cancer risks in Crohn disease patients","volume":"20","author":"Hemminki","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/ajg.2016.239","article-title":"Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan","volume":"111","author":"Wang","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2020.04.041","article-title":"Incidence of cancer after asthma development: 2 independent population-based cohort studies","volume":"147","author":"Woo","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Salameh, L., Mahboub, B., Khamis, A., Alsharhan, M., Tirmazy, S.H., Dairi, Y., Hamid, Q., Hamoudi, R., and Al Heialy, S. (2021). Asthma severity as a contributing factor to cancer incidence: A cohort study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0250430"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e35060","DOI":"10.1097\/MD.0000000000035060","article-title":"Association of asthma and lung cancer risk: A pool of cohort studies and Mendelian randomization analysis","volume":"103","author":"Huang","year":"2024","journal-title":"Medicine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11871","DOI":"10.1002\/cam4.5875","article-title":"Cancer incidence after asthma diagnosis: Evidence from a large clinical research network in the United States","volume":"12","author":"Guo","year":"2023","journal-title":"Cancer Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.18632\/oncotarget.14595","article-title":"Asthma and the risk of lung cancer: A meta-analysis","volume":"8","author":"Qu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1038\/s41598-021-84012-3","article-title":"Asthma and asthma symptom control in relation to incidence of lung cancer in the HUNT study","volume":"11","author":"Jiang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"23047","DOI":"10.1038\/s41598-024-74883-7","article-title":"Evidence of the association between asthma and lung cancer risk from mendelian randomization analysis","volume":"14","author":"Ye","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1081-1206(10)60632-1","article-title":"The association between allergies and cancer: What is currently known?","volume":"99","author":"Merrill","year":"2007","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10937400701436460","article-title":"Inflammation and lung cancer: Roles of reactive oxygen\/nitrogen species","volume":"11","author":"Azad","year":"2008","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1055-9965.EPI-18-1330","article-title":"Allergies and Asthma in Relation to Cancer Risk","volume":"28","author":"Kantor","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"20147","DOI":"10.1007\/s11356-022-23631-3","article-title":"Association between asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, and lung cancer in the US population","volume":"30","author":"Rahman","year":"2023","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3109\/0284186X.2014.1001497","article-title":"Cancer risk and mortality in asthma patients: A Swedish national cohort study","volume":"54","author":"Liu","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.2147\/COPD.S425735","article-title":"A Bibliometric Analysis of Comorbidity of COPD and Lung Cancer: Research Status and Future Directions","volume":"18","author":"Fang","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: Immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semcancer.2008.10.002","article-title":"Immune escape by Epstein-Barr virus associated malignancies","volume":"18","author":"Moormann","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"Perrett","year":"2005","journal-title":"Science"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients with Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","article-title":"Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose","volume":"25","author":"Harrison","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdt372","article-title":"Potential increased risk of cancer from commonly used medications: An umbrella review of meta-analyses","volume":"25","author":"Ioannidis","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO Guidelines on Inflammatory Bowel Disease and Malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn\u2019s Disease: Meta-Analysis of Placebo-Controlled Trials","volume":"6","author":"Deltenre","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of New or Recurrent Cancer in Patients with Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with meta-analysis: Malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.cgh.2024.03.032","article-title":"AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients with Malignancy: Commentary","volume":"22","author":"Axelrad","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kafel, A.J., Muzalyova, A., and Schnoy, E. (2025). Malignancy and Inflammatory Bowel Disease (IBD): Incidence and Prevalence of Malignancy in Correlation to IBD Therapy and Disease Activity-A Retrospective Cohort Analysis over 5 Years. Biomedicines, 13.","DOI":"10.3390\/biomedicines13061395"},{"key":"ref_107","first-page":"360","article-title":"The association of malignancy with rheumatic and connective tissue diseases","volume":"24","author":"Carsons","year":"1997","journal-title":"Semin. Oncol."},{"key":"ref_108","first-page":"388","article-title":"2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","volume":"84","author":"Sebbag","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: A systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides\u2014A follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Driscoll, C.B., Rich, J.M., Isaacson, D., Nicolas, J., Jiang, Y., Mi, X., Yang, C., Kocsuta, V., Goh, R., and Patel, N. (2025). Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis. Cancers, 17.","DOI":"10.3390\/cancers17030390"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e005247","DOI":"10.1136\/rmdopen-2024-005247","article-title":"Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: A nationwide Danish register-based cohort study","volume":"11","author":"Westermann","year":"2025","journal-title":"RMD Open"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"113928","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","article-title":"IL-23 inhibition for chronic inflammatory disease","volume":"404","author":"Jairath","year":"2024","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Wu, S., Xu, Y., Yang, L., Guo, L., and Jiang, X. (2023). Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1294416"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/ced\/llaf184","article-title":"Psoriasis vulgaris in patients with a recent history of neoplasia: Safety of interleukin-23 inhibitors. A multicentre retrospective study","volume":"50","author":"Satolli","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease","volume":"391","author":"Chapman","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_125","first-page":"e17","article-title":"Efficacy and Safety of Interleukin-12\/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"32","author":"Jaber","year":"2025","journal-title":"Am. J. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Biskup, L., Semeradt, J., Rogowska, J., Chort, W., Durko, \u0141., and Ma\u0142ecka-Wojciesko, E. (2025). New Interleukin-23 Antagonists\u2019 Use in Crohn\u2019s Disease. Pharmaceuticals, 18.","DOI":"10.3390\/ph18040447"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Wang, S., Sun, H., Wang, Q., and Xiao, H. (2025). Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1490667"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA Clinical Guidelines Committee AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e1913102","DOI":"10.1001\/jamanetworkopen.2019.13102","article-title":"Risk of Infections and Cancer in Patients with Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis","volume":"2","author":"Bilal","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Ru, Y., Ding, X., Luo, Y., Li, H., Sun, X., Zhou, M., Zhou, Y., Kuai, L., Xing, M., and Liu, L. (2021). Adverse Events Associated with Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.670398"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Battista, T., Gallo, L., Martora, F., Fattore, D., Potestio, L., Cacciapuoti, S., Scalvenzi, M., and Megna, M. (2024). Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13071940"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jamadermatol.2025.3928","article-title":"Comparative Cancer Risk in Patients with Psoriasis Treated with Adalimumab, Secukinumab, or Ustekinumab","volume":"161","author":"Schwarz","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-023-00905-3","article-title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_135","first-page":"1441","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: Analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.it.2013.07.004","article-title":"A balance of interleukin-12 and -23 in cancer","volume":"34","author":"Ngiow","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn\u2019s Disease: An Integrated Analysis of Phase II\/III Clinical Development Programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn\u2019s Disease: The IM-UNITI Trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_143","first-page":"251","article-title":"Advanced Combination Treatment with Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s10620-023-08014-z","article-title":"Efficacy and Safety of IL-12\/23 and IL-23 Inhibitors for Crohn\u2019s Disease: Systematic Review and Meta-Analysis","volume":"68","author":"Vuyyuru","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izac035","article-title":"Ustekinumab and Vedolizumab Are Not Associated with Subsequent Cancer in IBD Patients with Prior Malignancy","volume":"28","author":"Hong","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/jcpt.13781","article-title":"Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential","volume":"47","author":"Ghasemi","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: Opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"Luthra","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic Therapies and Risk of Infection and Malignancy in Patients with Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.3748\/wjg.v21.i15.4744","article-title":"Integrin antagonists are effective and safe for Crohn\u2019s disease: A meta-analysis","volume":"21","author":"Ge","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs","volume":"79","author":"Maintz","year":"2024","journal-title":"Allergy"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","article-title":"Dupilumab in Adults with Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study","volume":"160","author":"Beck","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Tanczosova, M., Hugo, J., and Gkalpakiotis, S. (2023). Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031191"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3000605241297551","DOI":"10.1177\/03000605241297551","article-title":"Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma","volume":"52","author":"Ferreira","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Jing, D., Cheng, J., Chen, X., Shen, M., and Liu, H. (2022). The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.923362"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous T-cell lymphoma following dupilumab use: A systematic review","volume":"62","author":"Park","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Amatore, F., Neildez, M., de Masson, A., Battistella, M., Tauber, M., Ingen-Housz-Oro, S., Droitcourt, C., Staumont-Sall\u00e9, D., and Beylot-Barry, M. (2026). Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.70407"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00384-012-1456-0","article-title":"Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer","volume":"27","author":"Formentini","year":"2012","journal-title":"Int. J. Color. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Zaazouee, M.S., Alwarraqi, A.G., Mohammed, Y.A., Badheeb, M.A., Farhat, A.M., Eleyan, M., Morad, A., Zeid, M.A.A., Mohamed, A.S., and AbuEl-Enien, H. (2022). Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.992731"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic Therapies for Severe Asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_165","first-page":"Cd012929","article-title":"Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma","volume":"10","author":"Gallagher","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): Two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab Treatment in Adults with Asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40264-017-0636-9","article-title":"Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review","volume":"41","author":"Braddock","year":"2018","journal-title":"Drug Saf."},{"key":"ref_169","first-page":"Cd010834","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: A European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cea.70067","article-title":"Spectrum and Impact of Reported Side Effects of Omalizumab in Patients with Chronic Urticaria: A Long-Term Multicentre Real-World Study","volume":"55","author":"Soegiharto","year":"2025","journal-title":"Clin. Exp. Allergy"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients with Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of \u201cReal-world\u201d Evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic Spontaneous Urticaria: A Review","volume":"332","author":"Kolkhir","year":"2024","journal-title":"JAMA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG Clinical Guideline: Management of Crohn\u2019s Disease in Adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"keaf522","DOI":"10.1093\/rheumatology\/keaf522","article-title":"The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs","volume":"65","author":"Bechman","year":"2025","journal-title":"Rheumatology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2502244","DOI":"10.1183\/13993003.02244-2025","article-title":"Addressing the global challenges of COPD and asthma: A shared vision from the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA)","volume":"67","author":"Halpin","year":"2026","journal-title":"Eur. Respir. J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"British Thoracic Society (BTS), and National Institute for Health and Care Excellence (NICE) (2025). BTS\/NICE\/SIGN joint guideline on asthma: Diagnosis, monitoring and chronic asthma management (November 2024)\u2014Summary of recommendations. Thorax, 80, 416\u2013424.","DOI":"10.1136\/thorax-2024-222910"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, Preventing, and Managing Treatment-Related Complications in Patients with Inflammatory Bowel Diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e2500170","DOI":"10.1200\/GO-25-00170","article-title":"Global Epidemiologic Trends of Early-Onset Cancers From 1990 to 2021 and Projection to 2040","volume":"12","author":"Kundu","year":"2026","journal-title":"JCO Glob. Oncol."},{"key":"ref_188","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2023.07.007","article-title":"A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders","volume":"39","author":"Finnegan","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"104642","DOI":"10.1016\/j.breast.2025.104642","article-title":"The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research","volume":"85","author":"Caballero","year":"2026","journal-title":"Breast"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/curroncol28020137","article-title":"Patient and Patient Group Engagement in Cancer Clinical Trials: A Stakeholder Charter","volume":"28","author":"Michaud","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41585-025-01096-6","article-title":"Digital twins for personalized treatment in uro-oncology in the era of artificial intelligence","volume":"23","author":"Brandl","year":"2026","journal-title":"Nat. Rev. Urol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"105171","DOI":"10.1016\/j.critrevonc.2026.105171","article-title":"Digital twins in oncology: From predictive modelling to personalised treatment strategies","volume":"220","author":"Olawade","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1038\/s41598-026-45272-z","article-title":"Digital twins: Past, present and future","volume":"16","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2024.13486","article-title":"Addressing AI Algorithmic Bias in Health Care","volume":"332","author":"Ratwani","year":"2024","journal-title":"JAMA"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"100414","DOI":"10.1016\/j.jcpo.2023.100414","article-title":"Impact of the COVID-19 pandemic on cancer care in Ireland\u2014Perspectives from a COVID-19 and Cancer Working Group","volume":"36","author":"Murray","year":"2023","journal-title":"J. Cancer Policy"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41523-025-00768-1","article-title":"Advancing equitable access to innovation in breast cancer","volume":"11","author":"Luis","year":"2025","journal-title":"npj Breast Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/445\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:22:55Z","timestamp":1785241375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":197,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080445"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080445","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}